Related references
Note: Only part of the references are listed.Heparin/PF4 antibodies formation after heparin treatment: Temporal aspects and long-term follow-up
Anna Vittoria Mattioli et al.
AMERICAN HEART JOURNAL (2009)
Studies of the immune response in heparin-induced thrombocytopenia
Theodore E. Warkentin et al.
BLOOD (2009)
False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus
R. Pauzner et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia
T. Bakchoul et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital
Makiko Ban-Hoefen et al.
THROMBOSIS RESEARCH (2009)
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy
Gustavo B. F. Oliveira et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion
Zhihua Xiao et al.
BLOOD (2008)
Treatment and prevention of heparin-induced thrombocytopenia
Theodore E. Warkentin et al.
CHEST (2008)
Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays
T. E. Warkentin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Heparin-induced thrombocytopenia - therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes
K. Krauel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
Marco Guerrini et al.
NATURE BIOTECHNOLOGY (2008)
Outbreak of Adverse Reactions Associated with Contaminated Heparin
David B. Blossom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Contaminated heparin associated with adverse clinical events and activation of the contact system
Takashi Kei Kishimoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia
Tyree H. Kiser et al.
PHARMACOTHERAPY (2008)
Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings
A. Greinacher et al.
THROMBOSIS RESEARCH (2008)
What is the potential for overdiagnosis of heparin-induced thrombocytopenia?
Gregory K. Lo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes
A. Greinacher et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia
C. Pouplard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital
Maureen A. Smythe et al.
CHEST (2007)
Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: Results of the CHOOSE-ON trial
Andreas Koster et al.
ANNALS OF THORACIC SURGERY (2007)
Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery
Brendan M. Everett et al.
ANNALS OF THORACIC SURGERY (2007)
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Theodore E. Warkentin et al.
BLOOD (2006)
Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies
Andreas Greinacher et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Heparin-induced thrombocytopenia
Gowthami M. Arepally et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia
Leigh E. Efird et al.
ANNALS OF PHARMACOTHERAPY (2006)
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings
GK Lo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
TE Warkentin et al.
BLOOD (2005)
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?
TE Warkentin et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2005)
Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3
N Lubenow et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Risk for heparin-induced thrombocytopenia. with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
N Martel et al.
BLOOD (2005)
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome - A nested cohort study
TE Warkentin et al.
CHEST (2005)
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
L Rauova et al.
BLOOD (2005)
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia
JI Zwicker et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass
A Lillo-de Louët et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients
TE Warkentin et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia
A Greinacher et al.
CIRCULATION (2003)
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
BE Lewis et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Heparin-induced thrombocytopenia: pathogenesis and management
TE Warkentin
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia
L Alberio et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia
LE Carlsson et al.
PHARMACOGENETICS (2003)
Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin induced thrombocytopenia
AP Hong et al.
BLOOD (2003)
Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery
JL Francis et al.
ANNALS OF THORACIC SURGERY (2003)
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin
E Lindhoff-Last et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Delayed-onset heparin-induced thrombocytopenia and thrombosis
TE Warkentin et al.
ANNALS OF INTERNAL MEDICINE (2001)
Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8
GM Arepally et al.
BLOOD (2001)
Temporal aspects of heparin-induced thrombocytopenia
TE Warkentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
B Pötzsch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
